TriSalus Life Sciences (TLSI) Receivables (2022 - 2026)

TriSalus Life Sciences (TLSI) has 5 years of Receivables data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 4.36% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 4.36% YoY), and the FY2025 full-year result was $6.6 million, up 28.59% from the prior year.
• Receivables for Q1 2026 stood at $5.2 million, down from $6.6 million in the prior quarter.
• Across five years, Receivables topped out at $6.6 million in Q4 2025 and bottomed at $1.6 million in Q4 2022.
• The 5-year median for Receivables is $5.0 million (2024), against an average of $4.6 million.
• The widest annual swing landed in 2023, when Receivables surged 131.21%; it then decreased 4.36% in 2026.
• A 5-year view of Receivables shows it stood at $1.6 million in 2022, then soared by 131.21% to $3.6 million in 2023, then soared by 41.67% to $5.1 million in 2024, then gained by 28.59% to $6.6 million in 2025, then decreased by 20.48% to $5.2 million in 2026.
• The last three Receivables figures came in at $5.2 million (Q1 2026), $6.6 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.

Peer Comparison